Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BAMF Health

Request full access

Precision medicine for cancer patients

Grand Rapids, United StatesFounded 2018Biotech & Life Sciences

About BAMF Health

BAMF Health, established in 2018, is a healthcare company focused on the field of theranostics, a specialized approach that combines diagnostics and therapy. The company was founded by Dr. Anthony Chang, who serves as the CEO. Dr. Chang’s background as a quantitative imaging scientist and his experience in molecular imaging and nanomedicine directly inform the company's scientific direction and its focus on precision medicine. The company's establishment was significantly bolstered by a $30.2 million series D funding round which enabled the construction of its headquarters and main clinic in Grand Rapids, Michigan.

The core of BAMF Health's business revolves around providing intelligence-based precision medicine, primarily for cancer detection and treatment. It operates what it describes as the world's most advanced theranostics center, which includes a cyclotron-equipped radiopharmacy, a molecular imaging clinic, and a systemic radiotherapy clinic. This integrated facility allows the company to diagnose and treat diseases with a high degree of precision. The business model centers on offering these advanced diagnostic and treatment services directly to patients, particularly those with late-stage cancers like prostate cancer. Furthermore, BAMF Health engages in conducting clinical trials for new radiopharmaceuticals, creating an additional revenue stream and positioning itself at the forefront of medical research in its niche.

The services provided by BAMF Health utilize advanced radiopharmaceuticals for both imaging and treatment. For prostate cancer, the company employs PSMA (prostate-specific membrane antigen) targeted agents. A gallium-68 based radiotracer is used with PET/CT scans for diagnosis, allowing for detailed visualization of cancer cells throughout the body. For treatment, a lutetium-177 based radiopharmaceutical is administered, which delivers targeted radiation directly to the cancer cells, minimizing damage to surrounding healthy tissue. This dual capability of diagnosing and then treating with molecularly similar compounds is the essence of their theranostic platform, which aims to improve patient outcomes and quality of life.

Source: Dealroom company data

BAMF Health in the Grand Rapids ecosystem

Live from Dealroom

The BAMF Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States91%
🇵🇭 Philippines4%
🇸🇬 Singapore2%
🇸🇪 Sweden1%
🇽🇰 Kosovo1%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about BAMF Health on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BAMF Health on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.